



Title: Importance of peptidoglycan hydrolases, bactericidal enzymes produced by lactic acid bacteria, in the reduction of antibiotic resistance

Authors: LOPEZ-ZAMUDIO, Amairany, MENDOZA-GARCÍA, Patricia Guillermina, PEÑAMONTES, Carolina and FONSECA-BARRERA, Itzel del Carmen

Editorial label ECORFAN: 607-8695

BCIERMMI Control Number: 2021-01

BCIERMMI Classification (2021): 271021-0001

Pages: 15

RNA: 03-2010-032610115700-14

ECORFAN-México, S.C.

143 – 50 Itzopan Street

La Florida, Ecatepec Municipality

Mexico State, 55120 Zipcode

Phone: +52 1 55 6159 2296

Skype: ecorfan-mexico.s.c.

E-mail: contacto@ecorfan.org

Facebook: ECORFAN-México S. C.

Twitter: @EcorfanC


www.ecorfan.org

Holdings

Mexico	Colombia	Guatemala
Bolivia	Cameroon	Democratic
Spain	El Salvador	Republic
Ecuador	Taiwan	of Congo
Peru	Paraguay	Nicaragua

Antibiotics

Its induced the death or inhibiting the growth of bacteria and fungi, and the replication of viruses are defined as antimicrobial



Worldwide problem of antibiotic use

Antibiotic resistance (AR)

Factors that favor AR:

- The inappropriate use of antimicrobials
- The low quality of active compounds
- The lack or deficiency of infection prevention and control programs
- The inability of laboratories to detect resistance
- The inadequate surveillance and insufficient regulation of antibiotic use

Natural expression of bacterial evolution and genetics

Mechanisms of transferring resistance genes

Transformation

The transfer of genes from free DNA of a previously lysed bacterium to another


Conjugation

The transfer of genetic material contained in plasmids from one bacterium to another via pili

Transposition

The transfer of genetic material from one bacterium to another by a phage

Mechanism of bacterial resistance to antibiotics



Examples of recent cases of antibiotic resistance

2014-2015:

Acinetobacter baumannii showed of resistance to fluoroquinolones, amikacin, trimethoprim/sulfamethoxazole, imipenem, meropenem, cephalosporins and tetracyclines

2016:

Enterococcus faecalis and *Enterococcus faecium* strains, which showed resistance to ampicillin, streptomycin, penicillin, vancomycin, gentamicin, erythromycin and quinupristin and dalfopristin

2017:

Pseudomonas aeruginosa showed of resistance to to ampicillin, ceftriaxone, chloramphenicol, cefotaxime cephalothin, nitrofurantoin, kanamycin, streptomycin and tetracycline

2017:

Escherichia coli showing resistance to amikacin, ampicillin, levofloxacin, cephalothin, cefotaxime, ceftriaxone, chloramphenicol, gentamicin, netilmicin, nitrofurantoin, cefepime, trimethoprim sulfamethoxazole, tetracycline, kanamycin and streptomycin

2018:

strains of *Staphylococcus aureus* and 12 strains of coagulase-negative *Staphylococcus* showing methicillin resistance

Worldwide action plan on antibiotic resistance

Priority 1: CRITICAL	Priority 2: HIGH	Priority 3: MEDIUM
<p>Carbapenem-resistant <i>Acinetobacter baumannii</i></p> <p>Carbapenem-resistant <i>Pseudomonas aeruginosa</i></p> <p>Carbapenem-resistant <i>Enterobacteriaceae</i>, producers of extended-spectrum beta-lactamases.</p>	<p><i>Enterococcus faecium</i>, resistant to vancomycin</p> <p><i>Staphylococcus aureus</i>, methicillin-resistant, intermediate susceptible and vancomycin resistant</p> <p><i>Helicobacter pylori</i>, resistant to clarithromycin</p> <p><i>Campylobacter spp.</i>, resistant to fluoroquinolones</p> <p><i>Salmonellae</i>, resistant to fluoroquinolones</p> <p><i>Neisseria gonorrhoeae</i>, cephalosporin-resistant,</p>	<p><i>Streptococcus pneumoniae</i>, not penicillin sensitive</p> <p>Ampicillin-resistant <i>Hemophilus influenzae</i></p> <p>Fluoroquinolone-resistant <i>Shigella spp.</i></p>

WHO in 2017 published the first list of priority AR pathogens

Development of the presence of antimicrobial resistance in Mexico

1998

Streptococcus pneumoniae
Showed show resistance to penicillin and to cephalosporins, macrolides, ciprofloxacin, trimethoprim-sulfamethoxazole, chloramphenicol and tetracyclines

2009

Multidrug-resistant *Salmonella typhimurium* strains

2011


Increasing resistance to clarithromycin was reported in *Helicobacter pylori*

2012

Antimicrobial resistance in *Campylobacter spp*

Alternative for controlling antibiotic use

Use of microorganisms with antimicrobial activity



Proteins of lactic acid bacteria with biological activities


Metabolite	Producing microorganism	Reference
Diacetyl	Most of the BAL	Montville and Winkowski, 1997
Reuterin	<i>L. reuteri</i> <i>L. coryniformis</i>	Magnusson and Schnürer, 2001
BLIS: Bacteriocin-like and inhibitory substances	Most of the BAL	Montville and Winkowski, 1997
Bacteriocins	Most of the BAL	Nes, et al., 1996
Cyclic dipeptides: Cyclo-PhePro	<i>L. coryniformis</i>	Magnusson and Schnürer, 2001
Cyclo-PheOHPro	<i>L. plantarum</i>	
Cyclo-GlyLeu	<i>L. pentosaceus</i>	
Bioactive peptides	Most of the BAL	Visser, S. et al., 1986. Fedorov et al., 2003 Cibik and Chapot-Chartier, 2004, Lortal and Chapot-Chartier, 2005 Turner et al., 2007
PGH	Most of the BAL	

LAB have the ability to inhibit the growth of certain altering and/or harmful microorganisms in food or even within the community

Peptidoglycan hydrolases (PGH)

Enzymes that hydrolyzed in a controlled way the peptidoglycan bond inhibiting the growth of bacteria that represent a public health problem.

Classification



The classification of PGHs depends on the type of bond they hydrolyze in the PG

Catalytic domains of peptidoglycan hydrolases

The characterized PGHs have a modular structural organization with two domains: a catalytic domain containing the active site of the enzyme and a cell wall binding domain

Catalytic domains

Catalytic domains are specialized for cleavage of a specific peptidoglycan bond.

N-acetylmuramoyl-L-alanine amidase	Endopeptidase	Carboxypeptidase	N-acetylglucosaminidase	N-acetylmuramidase
Amidase 2 (PF01510)	Peptidase M23 (PF01551)	Peptidase_S66 (PF02016)	Glucosaminidase (PF01832)	Glico_hydro_25 (PF01183)
Amidase 3 (PF01520)	CHAP (PF05257)	VanY (PF02557)		SLT (PF01464)
Amidase 5 (PF05382)		Peptidase_S11 (PF02113)		Transglucosylase (PF06737)
CHAP (PF05257)		Peptidase_S13 (PF00768)		

Cell wall binding domains

Cell wall binding domains are of great importance for the catalytic efficiency of PGHs. One of their main functions is the binding of proteins to the cell wall and the targeting of the enzyme to its site of action

Binding domains	Joint sites	XFAM access number
Big_4	Variety of bacterial surface proteins.	PF07532
CBM_5_12	Carbohydrate Binding Modulus (CBM)	PF02839
ChW	Proteins containing ChW repeats (tryptophan)	PF07538
Collagen	Triple helix repeat proteins	PF01391
CpL_7	The CW_7 repeats form a cell wall binding motif.	PF08230
Cu_amine_oxidN ₁	Oxidation of primary amines to aldehydes	PF07833
Cw_binding_1	Repeats in P15057 recognition of choline-containing cell walls	PF01473

27 surface domains that can be found in bacteria

PGH production by lactic acid bacteria

The most reported production of PGH is *Lactobacillus*. One species can produce two or even three enzymes with this lytic activity

PGH	Sensitive strain
Muramidase	<i>Oenococcus oeni</i> , <i>Clostridium tyrobutyricum</i> , <i>Escherichia coli</i> , <i>Staphylococcus aureus</i> <i>Bacillus subtilis</i>
Streptococcus agalactiae bacteriophage B30 endolysin	<i>Streptococcus agalactiae</i> , <i>Streptococcus uberis</i> <i>Staphylococcus aureus</i>
PGHs isolated from <i>Pediococcus acidilactici</i> ATCC 8042	<i>Staphylococcus aureus</i>

Examples of Recombinant peptidoglycan hydrolases

Cloning of a PGH from *Lactobacillus gasseri* JCM11 31. Two recombinant plasmids, holgaY and lysgaY, were produced. the gene revealed significant homology with hypothetical muramidases from the phage *Lactobacillus* Badh, Lj965, Lj928, LL-H, mv4 and mv1

The AtlL protein from *Staphylococcus lugdunensis* was characterized for the first time and cloned in *E. coli*.

The pET system (pET System, Novagen) was used with *Escherichia coli* strain BL21(DE3) for cloning and expression from *Pediococcus acidilactici* ATCC 8042 .

Application of peptidoglycan hydrolases

Antimicrobial activity against resistant microorganisms

The food industry:

- ❖ Lysozyme is used in foods such as meats, sausages, fish, vegetables, fruits, wine and milk powder.
- ❖ Egg lysozyme is listed as a food additive.
- ❖ Lysostaphin is an enzyme produced by *Staphylococcus simulans*.

PGH	Isolated microorganism	Inhibited microorganism	Reference
Acp	<i>Clostridium perfringens</i>	<i>Micrococcus lysodeikticus</i> ATCC4698, <i>Bacillus subtilis</i> , <i>Clostridium difficile</i> and <i>Clostridium perfringens</i>	Camiade et al., 2010
N-acetylglucosamidase	<i>Pediococcus acidilactici</i> 99 kDa	<i>Streptococcus pyogenes</i> , <i>Enterococcus faecium</i> , <i>Lactobacillus paracasei</i> , <i>Listeria monocytogenes</i> , <i>Pediococcus acidilactici</i> ATCC 8042, <i>Enterococcus faecalis</i> and <i>Staphylococcus aureus</i> ATCC 6538	García-Cano et al., 2015
AtID	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i> , <i>Enterococcus faecalis</i> ATCC, <i>Enterococcus faecalis</i> , <i>Listeria innocua</i> , <i>Staphylococcus aureus</i> ATCC 6538	Serrano-Maldonado et al., 2018.

Conclusions

The overuse of antibiotics is a global public health problem, an alternative to this problem is the use of therapies with lytic enzymes such as PGH produced by BAL.

New bactericidal compounds of natural origin can be designed to replace antibiotics in the health, agricultural and agri-food sectors.

References

- Alós, J. I. (2015). Bacterial resistance to antibiotics: a global crisis. *Infectious Diseases and Clinical Microbiology*, 33(10), 692-699. doi:10.1016/j.eimc.2014.10.004.
- Arredondo-García, J. L., Echeguren, F. A. M., Arzate, B. P. and Medina-Cortina, J. H. (2018) Antimicrobial susceptibility of *Enterococcus faecalis* and *faecium* in a tertiary hospital. *Latin American Journal of Pediatric Infectious Diseases*. 31(2), 56-61.
- Baker J.R., Liu C., Dong S. and Pritchard D.G. 2006. Endopeptidase and glycosidase activities of the bacteriophage B30 lysin. *Appl Environ Microbiol*. 72(10):6825-6828.
- Bautista-Márquez A, Richardson V, Ortiz-Orozco O, Luna-Cruz ME, Carnalla-Barajas MN, Echaniz-Avilés G, Bobadilla-del Valle M, Martínez-Medina L, Montalvo-Vázquez AM, de la Re-Montaño N, Anchondo-Martínez I, Tinoco-Favila JC, Martínez-Aguilar G, Yberri-Zárate I, Girón-Hernández JA, Sifuentes-Osornio J, Guerrero ML, Ruiz-Palacios GM. Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age. *Arch Med Res*. 2013 Feb;44(2):142-50. doi: 10.1016/j.arcmed.2012.12.005. Epub 2013 Jan 4. PMID: 23291380.
- Cabrera, C. E., Gómez, R. F., and Zúñiga, A. E. (2007). Bacterial resistance to antibiotics, antiseptics and disinfectants a manifestation of survival and adaptation mechanisms. *Medical Colombia*, 38(2), 149-158.
- Calvo, J., and Martínez-Martínez, L. (2009). Mechanisms of action of antimicrobials. *Infectious Diseases and Clinical Microbiology*, 27(1), 44-52. doi:10.1016/j.eimc.2008.11.001
- Camiade, E., Peltier, J., Bourgeois, I., Couture-Tosi, E., Courtin, P., Antunes, A., Chapot-Chartier, M. P., Dupuy, B., & Pons, J. L. (2010). Characterization of Acp, a peptidoglycan hydrolase of *Clostridium perfringens* with N-acetylglucosaminidase activity that is involved in cell separation and stress-induced autolysis. *Journal of bacteriology*, 192(9), 2373-2384. <https://doi.org/10.1128/JB.01546-09>
- De Moreno de LeBlanc, A., Matar, C., LeBlanc, N. and Perdígón, G. 2005. Effects of milk fermented by *Lactobacillus helveticus* R389 on a murine breast cancer model. *Breast cancer res*. 7(4): R477- R486.
- Díaz, E., López, R. and García, J.L. 1991. Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits. *J Biol Chem*. 266(9): 5464-5471.
- Donovan, D. M., Foster-Frey, J., Dong, S., Rousseau, G.M., Moineau, S., and Pritchard, D.G. 2006. The cell lysis activity of the *Streptococcus agalactiae* bacteriophage B30 endolysin relies on the cysteine, histidine-dependent amidohydrolase/peptidase domain. *Appl Environ Microbiol*, 72(7): 5108- 5112.
- García-Cano, I., Campos-Gómez, M., Contreras-Cruz, M., Serrano-Maldonado, C.E., González-Canto, A., Peña-Montes, C., Rodríguez-Sanoja, R., Sánchez, S. and Farrés, A. 2015. Expression, purification, and characterization of a bifunctional 99-kDa peptidoglycan hydrolase from *Pediococcus acidilactici* ATCC 8042. *Appl Microbiol Biotechnol*. 99(20): 8563-8573.
- Hernández-Ledesma, B., Miralles, B., Amigo, L., Ramos, M. and Recio, I. 2005. Identification of antioxidant and ACE-inhibitory peptides in fermented milk. *J. Sci. Food Agric*. 85(6): 1041–1048.
- Joris, B., Englebert, S., Chu, C.P., Kariyama, R., Daneo-Moore, L., Shockman, G.D. and Ghuyssen, J.M. 1992. Modular design of the *Enterococcus hirae* muramidase-2 and *Streptococcus faecalis* autolysin. *FEMS Microbiol Lett*. 70(3):257–264.
- Layec, S., Decaris, B. and Leblond-Bourget, N. 2008. Diversity of Firmicutes peptidoglycan hydrolases and specificities of those involved in daughter cell separation. *Res microbiol*. 159(7-8):507–515.
- Leblanc, J.G., Matar, C., Valdez, J.C., Leblanc, J. and Perdigon, G. 2002. Immunomodulating effects of peptidic fractions issued from milk fermented with *Lactobacillus helveticus*. *J Dairy Sci*. 85(11), 2733-2742.
- World Health Organization. (2017). WHO publishes list of bacteria for which new antibiotics are urgently needed. Retrieved from: <https://www.who.int/es/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>



ECORFAN®

© ECORFAN-Mexico, S.C.

No part of this document covered by the Federal Copyright Law may be reproduced, transmitted or used in any form or medium, whether graphic, electronic or mechanical, including but not limited to the following: Citations in articles and comments Bibliographical, compilation of radio or electronic journalistic data. For the effects of articles 13, 162,163 fraction I, 164 fraction I, 168, 169,209 fraction III and other relative of the Federal Law of Copyright. Violations: Be forced to prosecute under Mexican copyright law. The use of general descriptive names, registered names, trademarks, in this publication do not imply, uniformly in the absence of a specific statement, that such names are exempt from the relevant protector in laws and regulations of Mexico and therefore free for General use of the international scientific community. BCIERMMI is part of the media of ECORFAN-Mexico, S.C., E: 94-443.F: 008- (www.ecorfan.org/booklets)